Profound Medical Corp. (PROF)

Profound Medical Income Statement

Financials in millions CAD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	7.25	7.2	6.68	6.87	7.3	4.17
Revenue Growth (YoY)	1.00%	7.75%	-2.79%	-5.90%	74.99%	60.40%
Cost of Revenue	2.81	2.82	3.66	3.92	3.83	1.78
Gross Profit	4.44	4.38	3.02	2.95	3.47	2.39
Selling, General & Admin	19.23	18.62	17.93	17.97	12.43	7.9
Research & Development	14.47	14.38	14.69	15.28	9.91	9.4
Other Operating Expenses	0	0	2.52	0	0	0
Operating Expenses	33.7	33	35.15	33.24	22.34	17.29
Operating Income	-29.26	-28.62	-32.13	-30.29	-18.86	-14.9
Interest Expense / Income	-0.36	0.08	-3.74	0.3	2.71	0.17
Other Expense / Income	-1.14	4.81	-12.09	-0.18	2.8	4.49
Pretax Income	-27.76	-33.5	-16.29	-30.42	-24.38	-19.57
Income Tax	-0.14	-0.13	0.29	0.11	0.05	0.15
Net Income	-27.62	-33.38	-16.58	-30.52	-24.42	-19.71
Shares Outstanding (Basic)	21	21	21	21	20	12
Shares Change	2.35%	2.35%	0.51%	5.83%	65.58%	-
EPS (Basic)	-1.29	-1.35	-1.38	-1.50	-1.25	-1.37
EPS (Diluted)	-1.29	-1.35	-1.38	-1.50	-1.25	-1.37
Free Cash Flow	-21.57	-22.3	-25.8	-22.39	-20.57	-15.05
Free Cash Flow Per Share	-1.01	-1.04	-1.24	-1.08	-1.05	-1.27
Gross Margin	61.22%	60.87%	45.22%	42.95%	47.56%	57.26%
Operating Margin	-403.64%	-397.50%	-480.86%	-440.72%	-258.26%	-357.07%
Profit Margin	-381.07%	-463.61%	-248.14%	-444.06%	-334.39%	-472.26%
Free Cash Flow Margin	-297.59%	-309.72%	-386.17%	-325.80%	-281.68%	-360.57%
EBITDA	-26.95	-32.28	-18.43	-28.23	-20.13	-17.88
EBITDA Margin	-371.78%	-448.34%	-275.87%	-410.78%	-275.56%	-428.44%
Depreciation & Amortization	1.17	1.15	1.6	1.88	1.54	1.51
EBIT	-28.12	-33.42	-20.04	-30.11	-21.67	-19.39
EBIT Margin	-387.89%	-464.26%	-299.88%	-438.12%	-296.62%	-464.64%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).